# LIPFENDRA (enlicitide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/enlicitide

> LIPFENDRA (enlicitide), sponsored by Merck & Co., Inc. (MRK): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | LIPFENDRA (enlicitide) |
| Codes | MK-0616 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | with hyperlipidemia, with hypercholesterolemia, [Hyperlipidemia](https://sec-api.dev/indications/hyperlipidemia) |
| Modality | peptide |
| FDA designations | none disclosed |

## Timeline

### Jun 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: with hyperlipidemia.
- First seen 2025-08-05, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0000310158-25-000059): "In June 2025, Merck announced positive topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of MK-0616, enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for the treatment of adults with hyperlipidemia on lipid-lowering therapies, including at least a statin." https://www.sec.gov/Archives/edgar/data/310158/000031015825000059/mrk-20250930.htm
- SEC Form 10-Q (accession 0000310158-25-000014): "In June 2025, Merck announced positive topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of MK-0616, enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for the treatment of adults with hyperlipidemia on lipid-lowering therapies, including at least a statin." https://www.sec.gov/Archives/edgar/data/310158/000031015825000014/mrk-20250630.htm

### Sep 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: with hypercholesterolemia.
- First seen 2025-11-05, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0000310158-25-000059): "In September 2025, Merck announced positive topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for the treatment of adults with hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance)." https://www.sec.gov/Archives/edgar/data/310158/000031015825000059/mrk-20250930.htm

### August 3, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hyperlipidemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07216482 (A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07216482

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hyperlipidemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07216482 (A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07216482

## Same indication

- [Lipfendra (enlicitide decanoate)](https://sec-api.dev/pdufa/enlicitide-decanoate) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/enlicitide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LIPFENDRA (enlicitide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/enlicitide

```bibtex
@misc{secapidev_pdufa_enlicitide_20261116,
  title        = {LIPFENDRA (enlicitide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/enlicitide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_enlicitide_20261116","title":"LIPFENDRA (enlicitide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/enlicitide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
